Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
ACC 25: The EKSTROM Trial
Author(s): Matthew J Budoff Added: 1 month ago
ACC 2025 - Outcomes from colchicine in patients with stable coronary artery disease (CAD) shows significant plaque volume progression compared to placebo at one year.Dr Matthew Budoff (UCLA Medical Centre, Los Angeles, US) joins us onsite at ACC 2025 to discuss findings from the randomized, placebo-controlled, investigator-initiated EKSTROM trial (NCT06342609; Lundquist Institute for Biomedical… View more

Intervention
Job title: President and Chief Executive Officer
AI in Quantitative CT Assessments: CONFIRM2 with Dr Alexander Van Rosendael
Author(s): Alexander van Rosendael , Dipti Itchhaporia Added: 6 months ago
In this episode of the "Innovations in Cardiology" series, host Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute, Newport Beach, CA, US) is joined by Dr Alexander Van Rosendael (Leiden University Medical Center, Leiden, NL) to discuss the findings from the CONFIRM2 trial. Conducted from up to 50 international clinical CCTA sites with 35,000 patients, CONFIRM2 aims to improve comprehensive… View more

Digital Health

Intervention
ESC 24: The EARTH-STEMI Meta-Analysis
Author(s): Gianluca Campo Added: 8 months ago
ESC Congress 2024 — Complete revascularisation is safe, reduces ischemic events for up to 4 years, and does not affect long-term mortality.We are joined onsite by Dr Gianluca Campo (University of Ferrara, Ferrara, IT) to discuss the findings from EARTH-STEMI. Previous RCTs have supported the benefit of complete revascularisation in the overall population, however, this has not been confirmed in… View more

Intervention
Job title: Clinical Professor of Medicine and Pharmacology
A Preferred Substrate-based Nomenclature in Myocardial Ischaemic Syndromes
Author(s): William E Boden , Juan Carlos Kaski , C Noel Bairey Merz , et al Added: 3 weeks ago

MI/ACS
REDUCE-IT: CV Outcomes With Icosapent Ethyl by Baseline LDL-C
Author(s): Deepak L Bhatt Added: 2 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants… View more

Prevention & Chronic Conditions
Decreased Noise Using a Novel Electrophysiology Recording System
Author(s): Josef Kautzner , Petr Peichl , Rune Paamand , et al Added: 1 year ago

Imaging & Diagnostics

Electrophysiology & Arrhythmia
THT 2025: The SUMMIT Trial
Author(s): Barry Borlaug Added: 2 months ago
THT Conference 2025 - Outcomes assessing the effect of obesity severity on tirzepatide in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) show that patients on tirzepatide with a greater reduction in BMI and baseline waist-to-height ratio had greater improvements in exercise capacity and KCCQ quality of life scores.Dr Barry Borlaug (Mayo Clinic and Foundation,… View more

Heart Failure

Prevention & Chronic Conditions
Research Area(s) / Expertise: Job title: Doctoral Student in the Department of Epidemiology